Eflornithine Cream
Indicated to mitigate facial hirsutism and formulated to target excessive hair growth.
Strengths: 13.9%
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Vaniqa
- Therapeutic class
Ornithine Decarboxylase Inhibitor
- Pharmacological class
Polyamine biosynthesis inhibitor
- Contraindications
hypersensitivity to eflornithine
- Minor side effects
acne; skin irritation; redness; stinging
- Moderate side effects
folliculitis; ingrown hair; dry skin; alopecia
- Serious side effects
anaphylaxis — requires immediate medical attention
- Dosage forms
Cream
- Administration route
Cutaneous use
- Prescription status
POM
- Manufacturer
Almirall
- Onset Time
4–8 weeks
- Duration
Ongoing use required
- Storage instructions
Store below 25°C, do not freeze.
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Pregnancy: Use only if strictly necessary. Breastfeeding: Caution advised.
Precautions and warnings
avoid contact with eyes; discontinue if irritation occurs; use only on the facial area
Patient summary
Indicated to mitigate facial hirsutism and formulated to target excessive hair growth.
Mechanism of action
Eflornithine irreversibly inhibits ornithine decarboxylase, the rate-limiting enzyme in polyamine synthesis, which is crucial for cell division and hair follicle development.
Eflornithine Cream
Indicated to mitigate facial hirsutism and formulated to target excessive hair growth.
Editorial Notes
- Active ingredient(s): Eflornithine
- Listed indication(s): Hirsutism
Available option
- 2 tubes - 13.9 %1265-13-9-pct-15120